Overview Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder Status: Completed Trial end date: 2011-10-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether RX-10100 are effective in the treatment of Major Depressive Disorder (MDD). Phase: Phase 2 Details Lead Sponsor: Rexahn Pharmaceuticals, Inc.